Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | ctDNA vs. pathological markers

Marla Lipsyc-Sharf • 4 Jun 2022
ASCO 2022
General

Marla Lipsyc-Sharf, MD, Dana-Farber Cancer Institute, Boston, MA, reflects on the use of circulating tumor DNA (ctDNA) in clinical practice, which will be used alongside traditional pathological markers. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Marla Lipsyc-Sharf

Validating ctDNA-based approaches in clinical trials
0:49
Validating ctDNA-based approaches in clinical trials
Marla Lipsyc-Sharf • 4 Jun 2022
ctDNA and late recurrence in high-risk, HR+, HER2- breast cancer
1:46
ctDNA and late recurrence in high-risk, HR+, HER2- breast cancer
Marla Lipsyc-Sharf • 4 Jun 2022

Related Videos

AI governance and validation in robotic cancer surgery
1:12
AI governance and validation in robotic cancer surgery
Marie Hanaoka • 1 Jul 2026
Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026
The content of VJOncology is intended for healthcare professionals